- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Eli Lilly and Company (LLY)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
888.03
930.00
52 wk Range
623.78
1,133.95
LLY Comments
Compiled here, all relevant comments and discussions regarding the LLY stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
Very overvaluaded
1100
LLY shares will be a good buy between $845 and $850 on Friday; resistance will be at $997 in the fourth week of April, representing a potential gain of 18%.
$930.35 (+6%)
1509
what coming
1100
1200
war
1500
LLY P/E 44,5 Novo P/E 13,4 :)
Thought a split was eminent
Flashcrash it's just a matter of when, days weeks months?
Baloon
Novo P/E...13, Lilly P/R...49, amid better outlook it is not reasonable....
it's people following the hype, I think it will backfire for fhem
Good results for Novo, bad otlook, but Lilly had good outlook on the same market with the same products? No prize pressures? How is it possible?
-31$ in a day, is that normal?
-56$, in a day
mhmd berry delayed FDA approval of their pill form weight loss drug. playing games. once they get approved like Norvo it will rocket +100 in a day.
Novo Nordisk had very bad results and is pulling down the market. Still see Eli Lilly hit 1400 later this year but it takes forever if it keeps tanking everytime it gets close to 1100
Split coming soon
This conSekera makes sense: Of course. According to our reviews, Novo is rated 4 stars and is trading at a 21% discount to its fair value. And that's after the stock rose about 9% after the announcement. Eli Lilly is negotiating at a 40% premium to its fair value. This is an action with a rating of 2 stars. In fact, this seems to me a great opportunity for exchange. If you invest in Eli Lilly, it may be worth making some profits and reinvesting them in Novo. Sekera: Of course. According to our reviews, Novo is rated 4 stars and is trading at a 21% discount to its fair value. And that's after the stock rose about 9% after the announcement. Eli Lilly is negotiating at a 40% premium to its fair value. This is an action with a rating of 2 stars. In fact, this seems to me a great opportunity for exchange. If you invest in Eli Lilly, it may be worth making some profits and reinvesting them in Novo.
1300 target and beyond now. . I found this article for you: - https://cl.bobcatolivemedia.info/news/analyst-ratings/eli-lilly-stock-rises-as-bernstein-reiterates-outperform-rating-93CH-4437147
Now a lifetime drug . I found this article for you: - https://cl.bobcatolivemedia.info/news/stock-market-news/less-than-two-years-after-stopping-obesity-drugs-weight-and-health-issues-return-study-finds-4437376
Big companies have digital soldiers just like the government.
AFS FUND - PORTFOLIO OF US PHARMACEUTICAL INDUSTRY STOCKS: YOU WILL ALSO BE PROTECTED FROM DEVALUATION AND CURRENCY FLUCTUATIONS.
The Trump administration is set to inject $233 billion into the US pharmaceutical manufacturing sector. The Trump administration wants to bring pharmaceutical production back to the US. Pharmaceutical companies are investing in the US to avoid tariffs. Following Trump's tariff threats on pharmaceuticals, major pharmaceutical companies such as Merck, AstraZeneca, and Johnson & Johnson announced investments. Merck announced a $1 billion investment in a facility in Delaware at the end of April, while UK-based pharmaceutical company AstraZeneca announced in July that it planned to invest $50 billion in the US for pharmaceutical production and R&D. Johnson & Johnson also announced in March that it would increase its US investment to over $55 billion within the next four years. Swiss-based Roche also announced that it would invest $50 billion in pharmaceuticals and diagnostics in the US within the next five years. Eli Lilly announced earlier this week that it plans to build a new $6.5 billion manufacturing facility in Texas.
Eli Lilly never made any real profit just government subsidies and taxpayers money. Sell Nazi LLY
...
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.